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Influence of maternal weight 
gain on birth weight: a 
gestational diabetes cohort
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ABSTRACT
Objective: Our objective was to evaluate gestational weight gain (GWG) patterns and their relation to 
birth weight. Subjects and methods: We prospectively enrolled 474 women with gestational diabetes 
mellitus (GDM) at a university hospital (Porto Alegre, Brazil, November 2009-May 2015). GWG was 
categorized according to the 2009 Institute of Medicine guidelines; birth weight was classified as 
large (LGA) or small (SGA) for gestational age. Adjusted relative risks (aRRs) and 95% confidence 
intervals (95% CIs) were determined. Results: Adequate GWG occurred in 121 women [25.5%, 95% 
CI: 22, 30%]; excessive, in 180 [38.0%, 95% CI: 34, 43%]; and insufficient, in 173 [36.5%, 95% CI: 32, 
41%]. In women with normal body mass index (BMI), the prevalence of SGA was higher in those 
with insufficient compared to adequate GWG (30% vs. 0%, p < 0.001). In women with BMI ≥ 25 kg/m2, 
excessive GWG increased the prevalence of LGA [aRR 2.58, 95% CI: 1.06, 6.29] and protected from 
SGA [aRR 0.25, 95% CI: 0.10, 0.64]. Insufficient vs. adequate GWG did not influence the prevalence 
of SGA [aRR 0.61, 95% CI: 0.31, 1.22]; insufficient vs. excessive GWG protected from LGA [aRR 0.46, 
95% CI: 0.23, 0.91]. Conclusions: One quarter of this cohort achieved adequate GWG, indicating that 
specific ranges have to be tailored for GDM. To prevent inadequate birth weight, excessive GWG in 
women with higher BMI and less than recommended GWG in normal BMI women should be avoided; 
less than recommended GWG may be suitable for overweight and obese women. Arch Endocrinol Metab. 
2018;62(1):48-56
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INTRODUCTION
G estational diabetes mellitus (GDM) is typically diagnosed approximately 24-28 weeks using 
an oral glucose tolerance test (1). Adverse outcomes 
associated with GDM include increased risk of maternal 
hypertensive disorders and cesarean section as well as 
perinatal risks of macrosomia, shoulder dystocia and 
hypoglycemia (2).
Maternal obesity contributes to GDM and, in an 
independent fashion, to many other adverse maternal 
pregnancy outcomes, including pregnancy hypertensive 
disorders, cesarean section, weight retention, and 
postpartum diabetes. Adverse outcomes for offspring, 
including congenital anomalies, macrosomia and 
indicated preterm delivery, are also increased (3). 
Excessive weight gain per se contributes to an increased 
prevalence of large for gestational age (LGA) and 
macrosomia (4).
In 2009, the American Institute of Medicine 
(IOM) updated their recommendations on weight gain 
in pregnancy without a specific recommendation for 
GDM (4). Weight gain has been evaluated in several 
GDM cohort studies, with variable frequencies of 
adequate, insufficient or excessive weight gain being 
reported (5-8).
The objectives of this study were to evaluate how 
the 2009 IOM recommendations on gestational 
weight gain (GWG) applied to a contemporary cohort 
of GDM pregnancies and how the patterns of GWG in 
GDM impacted birth weight.
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SUBJECTS AND METHODS
We studied a cohort of 508 women with GDM with 
singleton pregnancies, with at least one prenatal 
appointment, who delivered at Hospital de Clínicas de 
Porto Alegre (HCPA), a university hospital. HCPA is 
located in the Southern state of Brazil, Rio Grande do 
Sul (population ~11 million inhabitants) and provides 
medical care through the Sistema Único de Saúde 
(SUS), the national health system. In 2015, more 
than 600,000 general consultations were performed; 
approximately 4,000 babies were delivered; and the 
cesarean rate was 32.8% (9). From November 2009 to 
May 2015, all eligible women referred from primary care 
units were consecutively included; a multidisciplinary 
team provided prenatal care. Women gave their consent 
after being fully informed, and the authors signed the 
confidentiality document for data use. The hospital 
ethics committee approved the study protocol (number 
2010-0364). We followed the STROBE statement for 
the study report (10).
Thirty-four women were excluded: one due to an 
abortion, one for having congenital achondroplasia 
and 32 due to missing data on maternal weight or 
infant birth weight. GDM was diagnosed with a 75-g 
oral glucose tolerance test (OGTT) using the criteria 
of fasting plasma glucose ≥ 110 mg/dL or 2-h plasma 
glucose ≥ 140 mg/dL in 232 women (49%) (11). After 
2010, the International Association of Diabetes and 
Pregnancy Study Groups (IADPSG) recommendation 
was adopted; 242 (51%) of the women met these 
criteria (12).
Pregestational weight was self-reported, and pre-
pregnancy BMI was classified according to the World 
Health Organization criteria (13). Weight and height 
were measured with light clothes and no shoes. All 
women were prescribed a normocaloric diet, emphasizing 
the intake of low glycemic index carbohydrates and fiber-
rich food. Capillary glucose targets were ≤ 95 mg/dL for 
pre-meal and ≤ 120 mg/dL for 2-h postprandial measures 
(14). If goals were not met after 2 weeks of nutritional 
therapy, pharmacological treatment was initiated. Data on 
pregnancy evolution, delivery, and maternal and newborn 
outcomes were obtained from hospital registries.
Ethnicity was self-reported. Schooling was 
categorized as ≤ 11 years or > 11 years. Total weight 
gain was the weight measured at admission to delivery 
minus the pre-pregnancy weight; weight gains 
until diagnosis and from diagnosis to delivery were 
calculated. The 2009 IOM guidance on GWG by BMI 
was used, including the following ranges: underweight 
women, 12.5 to 18 kg; normal weight, 11.5 to 16 kg; 
overweight, 7 to 11 kg and obese, 5 to 9 kg (4). An 
A1C test was measured at booking (initial A1C test) 
and during the 3rd trimester (3rd trimester A1C test). 
Pregnancy-related hypertension disorders included any 
diagnosis of gestational hypertension or preeclampsia/
eclampsia (15), and the composite of maternal risk 
factors included hypertensive disorders of pregnancy 
plus smoking.
Newborns were classified as small for gestational 
age (SGA) or as LGA according to the Alexander 
birth weight chart (16), which is routinely used at our 
hospital. Macrosomia was defined as a term birth weight 
≥ 4,000 g, and preterm birth was defined as a delivery 
before the completion of 37 gestational weeks (17).
Plasma glucose was measured by the enzymatic 
method and an A1C test using HPLC (Variant II 
Turbo HbA1C, BioRad Laboratories, Hercules, CA, 
USA, aligned to DCCT recommendations).
Statistical analysis
We described the prevalence of adequate gestational 
weight gain as n (%) and evaluated the 95% confidence 
intervals [95% CIs]. Student’s t test, χ2 test, ANOVA, 
and Pearson correlation were applied as appropriate.
Relative risks (RR) and 95% CIs for SGA and LGA 
were determined according to maternal weight gain 
within normal or elevated BMI ranges (≥ 25 kg/m2). 
Skin color, living with a partner, schooling, gravidity, 
weight gain grouped by IOM category, fasting glucose 
at the time of the diagnostic test, use of pharmacologic 
treatment, 3rd trimester A1C test, and the composite of 
maternal risk factors were explored in univariable and 
multivariable models for SGA. For LGA analysis, we 
added family history of diabetes to the models. Poisson 
regression with robust estimation was employed in 
multivariable analyses. Variables were included if a 
p value of at least < 0.10 was obtained in univariable 
analysis or if considered clinically important (gravidity 
and maternal risk factor).
We used SPSS software version 18.8 for statistical 
analyses. Statistical significance was set at 0.05, two-
sided.
RESULTS
There were some slight differences in baseline clinical 
characteristics between women classified by the two 
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GDM diagnostic criteria (Table 1). We analyzed them 
as a single group because we assumed that dissimilarities 
were related to distinct profiles captured by each 
criterion. The main differences were observed for a 
family history of diabetes (54.3% vs. 42.6%, p = 0.011), 
pregestational BMI (29.4 ± 6.5 vs. 30.7 ± 7.0 kg/m2, 
p = 0.046); the 2-hour glucose in the diagnostic OGTT 
(170.7 ± 29.1 vs. 148.5 ± 37.1 mg/dL, p < 0.001); 
the baseline A1C value (5.7% ± 0.8% vs. 5.4% ± 0.6%, 
p < 0.001), the latter measurement being within the 
range of laboratory references (6.0%); and weight at 
delivery (84.0 ± 17.3 vs. 89.1 ± 18.5 kg, p = 0.002). 
No differences were found regarding key maternal and 
perinatal outcomes. 
Among the 474 women, only one had a BMI < 18.5 
kg/m2, and this case was analyzed in the normal BMI 
group; 119 had normal BMIs (n = 120, 25%, 95% CI: 
21, 29%); and 354 (75%, 95% CI: 71, 79%) had BMIs 
≥ 25 kg/m2. Adequate weight gain occurred in 121 
women [25.5%, 95% CI: 22, 30%], excessive in 180 
Table 1. Comparison of women with gestational diabetes according to two diagnostic criteria
Characteristic/outcome
Brazilian criteria
N = 232
IADPSG criteria
N = 242 p
Mean ± SD or % Mean ± SD or %
Maternal
Age (years) 31.4 ± 6.2 31.2 ± 6.7 0.755
White ethnicity 75.4 78.9 0.365
Education (> 11 years) 49.6 47.5 0.656
With partner 63.4 45.5 < 0.001
Pregnancies (n) 2.7 ± 1.6 2.8 ± 1.7 0.789
Current smoker 0.9 3.3 0.064
Family history of diabetes 54.3 42.6 0.011
Previous GDM 13.4 13.2 0.964
Pre-pregnancy BMI (kg/m2) 29.4 ± 6.5 30.7 ± 7.0 0.046
Systolic BP (mmHg)* 115.8 ± 11.9 117.0 ± 12.3 0.287
Diastolic BP (mmHg)* 72.5 ± 10.2 73.0 ± 9.8 0.591
Glycemia in the OGTT (mg/dL)**
Fasting
1 hour (n = 180)
2 hour
100.0 ± 27
–
170.7 ± 29.1 
n = 226
97.2 ± 16.4
178.4 ± 35.8
148.5 ± 37.1
n = 200
0.177
–
< 0.001
2nd trimester A1C test (%)*** 5.7 ± 0.8 5.4 ± 0.6 < 0.001
3rd trimester weight gain (kg) 2.0 ± 4.0 2.7 ± 4.2 0.066
Weight at delivery (kg) 84.0 ± 17.3 89.1 ± 18.5 0.002
Total gestational weight gain (kg) 10.5 ± 7.5 10.1 ± 7.9 0.598
Hypertensive disorders of pregnancy 13.8 12.0 0.556
Cesarean section 58.6 52.1 0.151
Offspring
Birth weight (g) 3,221.6 ± 578.7 3,246.6 ± 602.8 0.645
Birth weight category 0.681
SGA 9.9 12.0
AGA 78.9 75.6
LGA 11.2 12.4
Macrosomia 7.3 8.3 0.704
IADPSG: International Association of Diabetes in Pregnancy Study Groups; GDM: gestational diabetes mellitus; BMI: body mass index; BP: blood pressure; OGTT: oral glucose tolerance test; SGA: 
small for gestational age; AGA: adequate for gestational age; LGA: large for gestational age.
* n = 230 for the Brazilian criteria and 241 for the IADPSG criteria; ** n = 226 for the Brazilian criteria and 200 for the IADPSG criteria; *** n = 206 for the Brazilian criteria and 207 for the IADPSG 
criteria.
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[38%, 95% CI: 34, 43%] and insufficient in 173 [36.5%, 
95% CI: 32, 41%]. Pre-pregnancy hypertension was 
present in 12.4% of the women, and preeclampsia/
gestational hypertension was present in 9.5% of the 
women. The average gestational age at delivery was 
38 ± 1.5 weeks (range: 30-41 weeks), and the rate of 
cesarean section was 55.3%. The baseline characteristics 
of the 474 women according to gestational weight gain 
categories are presented in Table 2.
When demographic and social characteristics across 
GWG categories (insufficient vs. adequate vs. excessive) 
were analyzed, maternal age was higher in women with 
insufficient GWG compared to those with excessive gain 
(Table 2). Fasting plasma glucose (mg/dL) in the OGTT 
was available for all women (98 ± 18 vs. 98 ± 26 vs. 100 ± 
23, p = 0.455), 1 h glucose was available for 180 women 
(182 ± 35 vs. 185 ± 38 vs. 171 ± 34, p = 0.104) and 2 h 
glucose was available for 426 women (162 ± 31 vs. 162 
± 40 vs. 158 ± 35, p = 0.558). The initial A1C level was 
measured in 413 women at a mean gestational age of 31 
± 5.8 weeks and was similar across groups (5.6% ± 0.7% 
vs. 5.5% ± 0.8% vs. 5.7 % ± 0.8%, p = 0.070).
Women who gained insufficient weight were more 
likely to be receiving pharmacological treatment (insulin 
or oral agents) compared to those with adequate gain 
(58% vs. 40%, p = 0.009). Metformin treatment was 
less frequent in those with adequate weight gain (31%) 
compared to those with insufficient weight gain (47%, 
p = 0.023), but in the excessive weight gain group 
(42%), the rates were not different compared to the 
two other groups. Insulin use was similar across all 
three groups (19.0% vs. 13.2% vs. 16.1%, p = 0.407). 
The primary data on maternal weight gain by 
IOM category for the two BMI groups (normal and 
overweight/obese) are displayed in Table 3. Total 
weight gain increased significantly across the groups. 
Weight at delivery increased significantly across the three 
IOM categories in normal BMI women (63.3 ± 6.4 vs. 
69.9 ± 6.7 vs. 80.7 ± 7.3 kg, p = 0.001). In women with 
BMI ≥ 25 kg/m2, the average weight gain was almost 
10 kg higher in the excessive weight gain group.
Table 3 depicts offspring outcomes according to 
GWG categories. The mean ± SD birth weight was 
3.234± 591 g; 242 (51%) newborns were male; 52 
(11%) were SGA and 56 (12%) LGA; and 37 (7.8%) 
were macrosomic. The preterm birth rate was 16.5% 
and was similar across groups (insufficient, 20%, 
adequate, 13% and excessive, 16%, p = 0.315).
The Pearson correlation (r) between GWG and 
birth weight in normal BMI women was weak, 0.47 
(p < 0.001), with a coefficient of determination (r2) 
of 0.22; in the group with overweight/obesity, r was 
lower, 0.24 (p < 0.001), and r2 was 0.06. The overall r 
coefficient was 0.26 (p < 0.001), and r2 was 0.07.
We could not run univariable analyses in the 
normal BMI group due to the lack of SGA babies and 
the presence of only one LGA baby in the adequate 
gain category (Table 3). Pharmacological treatment, 
Table 2. Baseline characteristics of 474 women with gestational diabetes according to the 2009 Institute of Medicine weight gain categories
Characteristic
Weight gain category
p valueTotal
n = 474
Insufficient
n = 173 (36.5)
Adequate
n = 121 (25.5)
Excessive
n = 180 (38)
Age (years)& 31 ± 6.4 33 ± 6.0 31 ± 6.6 30 ± 6.5 0.001
White ethnicity 366 (77) 138 (80) 99 (82) 129 (72) 0.073
Education, > 11 years 230 (49) 84 (49) 57 (47) 89 (49) 0.924
With partner 257 (54) 101 (58) 67 (55) 89 (49) 0.232
Pregnancies (n) 2.7 ± 1.7 2.8 ± 1.6 2.9 ± 1.6 2.6 ± 1.7 0.347
Current smoker 10 (2) 4 (2.3) 2 (1.7) 4 (2.2) 0.920
Family history of diabetes 229 (48) 74 (43) 63 (52) 92 (51) 0.185
Previous GDM 63 (13) 26 (15) 15 (12) 22 (12) 0.699
Pre-pregnancy BMI (kg/m2) 30.1 ± 6.8 30.7 ± 7.8 29.2 ± 6.5 29.9 ± 5.8 0.194
Systolic BP (mmHg), n = 471 116 ± 12 115 ± 13 116 ± 12 118 ± 12 0.120
Diastolic BP (mmHg), n = 471 73 ± 10 73 ± 10 71 ± 9 74 ± 11 0.163
GDM: gestational diabetes mellitus; BMI: body mass index; BP: blood pressure. 
Data represent the mean ± standard deviation (SD) or n (%). ANOVA and Tukey’s test for multiple comparisons χ2 test and Z test for proportion with Bonferroni adjustment.
& Insufficient and excessive groups are significantly different. 
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excessive total GWG and excessive gain in the 3rd 
trimester were all statistically significant in the BMI ≥ 
25 kg/m2 group and were included in the multivariable 
model, as were gravidity and 3rd trimester A1C. A 
maternal risk factor composite was added to SGA 
model, and the fasting plasma glucose at the OGTT 
was added to the LGA model.
Analyses were run including the total GWG and 3rd 
trimester gain separately, with adequate weight gain as 
the reference category. Comparisons of the effect of 
insufficient GWG on LGA risk were also performed, 
with excessive GWG as reference. Overall, we analyzed 
328 pregnancies with 34 SGA and 42 LGA infants in 
multivariable models.
As observed in Table 4, the SGA risk decreased 75% 
with excessive total GWG and 23% with each kilogram 
gained during the third trimester but was not enhanced 
by insufficient weight gain. The LGA risk increased 
independently with total GWG; each kilogram gained 
in the 3rd trimester increased the risk by 10%. In 
Table 3. Pregnancy outcomes according to pre-pregnancy body mass index and 2009 Institute of Medicine weight gain categories in 474 women with 
gestational diabetes
Outcome according to BMI
Weight gain category
p value
Insufficient Adequate Excessive
BMI < 25 kg/m2 (n = 120) n = 54 n = 34 n = 32
Maternal
3rd trimester weight gain# -0.7 ± 4.6 2.4 ± 2.3 4.1 ± 5.3 < 0.001
Weight at delivery (kg)¶ 63.3 ± 6.4 69.9 ± 6.7 80.7 ± 7.3 < 0.001
Total weight gain (kg)¶ 6.8 ± 3.0 13.3 ± 1.3 22.6 ± 5.0 < 0.001
Hypertensive disorders of pregnancy 7 (13) 2 (6) 2 (6) 0.427
Cesarean section 24 (44) 18 (53) 16 (50) 0.722
Maternal risk factors 12 (22) 2 (6) 4 (13) 0.101
Offspring
Birth weight (g)# 2868 ± 478 3284 ± 368 3413 ± 454 < 0.001
Birth weight category < 0.001
SGA# 16 (30) 0 (0) 1 (3)
AGA£ 37 (69) 33 (97) 25 (78)
LGA& 1 (2) 1 (3) 6 (19)
BMI ≥ 25 kg/m2 (n = 354) n = 119 n = 87 n = 148
Maternal 
3rd trimester weight gain¶ 0.7 ± 2.8 2.2 ± 3.4 4.1 ± 4.3 < 0.001
Weight at delivery (kg)† 88.0 ± 18.0 88 ± 16.0 98 ± 14 < 0.001
Total weight gain (kg) ¶ 1.8 ± 3.1 8.2 ± 1.8 16.4 ± 5.8 < 0.001
Hypertensive disorders of pregnancy 11 (9) 12 (14) 27 (18) 0.110
Cesarean section 66 (56) 49 (56) 89 (60) 0.715
Maternal risk factors* 35 (29) 23 (26) 43 (29) 0.882
Offspring
Birth weight (g)† 3157 ± 642 3157 ± 569 3425 ± 586 < 0.001
Birth weight category < 0.001
SGA§ 12 (10) 17 (20) 6 (4)
AGA 94 (79) 64 (74) 113 (76)
LGA§ 13 (11) 6 (7) 29 (20)
* Maternal risk factors include: hypertensive disorders of pregnancy plus smoking.
BMI: body mass index; n: number; SGA: small for gestational age; AGA: adequate for gestational age; LGA: large for gestational age. Data represent the 
mean ± standard deviation (SD) or n (%).
ANOVA and Tukey’s test for multiple comparisons χ2 test and Z test for proportion with Bonferroni adjustment.
# insufficient group is significantly different from the adequate or excessive groups; £ insufficient and adequate groups were different; & insufficient and excessive groups 
were different; † insufficient and adequate groups were different from the excessive group; ¶ all groups were different; § adequate and excessive groups were different.
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addition to weight gain, pharmacological treatment 
increased the LGA risk in the model with total GWG 
(RR 2.60, 95% CI: 1.11, 5.81). In the model with 3rd 
trimester weight gain, the risks were also independently 
increased with pharmacological treatment (RR 2.38; 
95% CI: 1.10, 5.28) and 3rd trimester A1C (RR 1.72; 
95% CI: 1.28, 2.31). Both adequate and insufficient 
weight gain had a protective effect upon LGA risk 
when compared to excessive weight gain.
study populations and diagnostic criteria may explain 
this wide range (5-7,20,21). Maternal and offspring 
outcomes can be worsened if women enter pregnancy 
in the overweight or obese categories; deleterious 
effects are further magnified by excessive weight gain 
(22). The high frequency of excessive GWG found 
(38%) was expected, since up to 65% women were 
reported gaining more weight than recommended in 
several cohort studies in GDM (5,7,8,22). This is not 
exclusive to GDM pregnancies; a similar rate (32.9%) 
was observed in women in a large Brazilian cohort 
(n = 2,244) (23). Less than recommended GWG was 
33.4% in the latter cohort, close to our rate (36.5%) 
and to those described in GDM (up to 40% of women) 
(7,8). The influence of GWG on GDM outcomes may 
therefore be uncertain, leading to the conclusion by a 
National Institutes of Health committee that evidence 
was insufficient “because of inconsistency across studies 
and imprecise effect estimates” (24). 
We observed higher weight gain until GDM 
diagnosis followed by lower gain thereafter, as described 
in other studies (25,26); this reinforces the idea that 
more than intervention per se, being labeled GDM 
may increase treatment compliance (27). Moreover, 
we suppose that excessive weight might be perceived 
as deleterious by GDM mothers, since overweight and 
obese women gained approximately 5 kg less than their 
normal BMI counterparts along pregnancy. Women 
with insufficient weight gain in our cohort frequently 
needed pharmacological treatment; this association 
was also found in the Atlantic-DIP cohort, where 
insulin use was common in women with lower weight 
gain (5), in contrast to what was previously described 
(25). A possible explanation could be the presence of 
a more severe degree of metabolic disorder. We could 
not further explore this possibility because we did not 
measure insulin or C-peptide. We can speculate that 
this may in part also explain the interesting finding that 
women gaining insufficient weight were older than 
those with excessive weight gain. Another explanation 
for this latter finding could be ascribed to the presence 
of some degree of placental insufficiency in the oldest 
group or to compliance being greater due to their 
previous life experiences. 
Although excessive and insufficient weight gain were 
frequent, maternal outcomes seemed unaffected in our 
study, opposing findings described by other authors: 
a higher weight gain in GDM pregnancies increased 
risks of cesarean section (7,22) and pregnancy-related 
Table 4. Risk for small and large for gestational age babies in women 
with gestational diabetes with BMI ≥ 25 kg/m2 according to gestational 
weight gain
Risk factor
Multivariable analysis*
aRR [95% CI] p value
Small for gestational age 
Total GWG (adequate as reference)
Excessive 0.25 [0.10,0.64] 0.004a
Insufficient 0.61 [0.31,1.22] 0.161
3rd trimester weight gain (kg) 0.87 [0.81,0.95] 0.001a
Large for gestational age
Total GWG (adequate as reference)
Excessive 2.58 [1.06,6.29] 0.037b
Insufficient 1.17 [0.42,3.29] 0.768
3rd trimester weight gain (kg) 1.11 [1.05,1.17] < 0.001b
Total GWG (excessive as reference)
Adequate 0.39 [0.16,0.95] 0.037b
Insufficient 0.46 [0.23,0.91] 0.026
aRR [95% CI]: adjusted relative risk (95% confidence interval); GWG: gestational weight gain.
* Poisson regression with robust estimation.
a Adjusted for gravidity, pharmacological treatment, maternal risk factors, and 3rd trimester A1C.
b Adjusted for gravidity, fasting plasma glucose in the oral glucose tolerance test, pharmacological 
treatment, and 3rd trimester A1C.
COMMENTS
In this GDM cohort, adequate weight gain was attained 
by only one quarter of women. Those with normal 
BMI had increased SGA rates with insufficient weight 
gain. In women with overweight or obesity, excessive 
GWG increased the LGA risk and protected from SGA, 
while there was a trend towards a decreased risk of LGA 
when GWG was insufficient.
Overweight and obesity were frequent in our cohort 
(75%), with a rate quite similar to that described for type 
2 diabetes pregnancies, 80% (18), reflecting the pattern 
described in 49.1% of non-pregnant Brazilian women 
in a recent survey (19). Variable rates of obesity, 17 to 
71%, have been reported in GDM cohorts; different 
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hypertension by almost two-fold in Irish women with 
excessive weight gain (5).
Regarding offspring outcomes, we found that only 
7% of birth weight could be explained by maternal 
GWG. Despite this, normal BMI women who gained 
less than the recommended GWG delivered more SGA 
babies, while in overweight/obese women we did not 
observe this association. Furthermore, the SGA rate 
was close to that of the LGA rate for the whole group, 
an unexpected finding. We could speculate that close 
surveillance of diet and weight gain could eventually 
be an explanation for both an increased rate of SGA in 
normal BMI women and a decreased rate of LGA in 
women with adequate or insufficient weight gain, while 
in women with excessive GWG, high rates of LGA 
remained. In non-diabetic pregnancies, delivery of 
SGA or low birth weight babies (< 2,500 g) is associated 
with multiple factors, such as hypertension, smoking 
and insufficient weight gain (27). No difference in 
hypertension or smoking rates across the weight 
gain groups was found. High rates of SGA were not 
expected, as it is well established that GDM treatment 
per se does not increase this risk (28). However, 22% 
of birth weight was ascribed to GWG in normal BMI 
women in our study, which could partially explain our 
findings. Weight gain below recommendations was not 
related to increased rates of SGA in other GDM cohorts 
(8,25) nor was it in a type 2 diabetes cohort (18); of 
note, the results were not adjusted by pre-pregnancy 
BMI categories. Weight loss in GDM women with 
BMI ≥ 25 kg/m2 resulted in increased SGA in a large 
American cohort, despite protecting against LGA and 
macrosomia, although in the study, the last weight 
measurement was taken around a mean gestational age 
of 34.8 weeks (29). The linkage between SGA and poor 
maternal weight gain, which is stronger in underweight 
women, is not well established yet for other BMI 
categories in non-GDM pregnancies and not even in 
GDM, though it is described in large cohort studies 
and remains positive when adjusted for confounders 
such as smoking and hypertension (4). It is tempting to 
speculate that other factors such as vitamin D deficiency 
might play a role. Maternal vitamin D deficiency and 
an increased rate of SGA births have been previously 
described in our cohort (30).
Excessive birth weight is conditioned by maternal 
obesity and hyperglycemia as well as by excessive weight 
gain (21,31,32). The association of birth weight with 
maternal weight gain has been described in women 
with type 2 diabetes (18), in obese-only women 
(31), and in obese GDM women (33), reflecting the 
independent role of those factors. Gestational diabetes 
leads to excessive birth weight irrespective of diagnostic 
criteria (2), while proper treatment has been associated 
with decreased risk (28). In our cohort, as in others, 
higher rates of LGA were associated with excessive 
weight gain mainly in overweight and obese women 
(7,8,25). In the Atlantic-DIP cohort, adjusted risks 
of similar magnitude to ours were reported for LGA 
(5), while in another cohort, LGA was increased in 
obese, but not in overweight, women (6). It is worthy 
of consideration that those studies calculated GWG 
from the time of booking. The independent effects of 
hyperglycemia and weight gain on birth weight were 
recently quantified: an A1C test < 5.0% avoided 47% of 
LGA, while adequate GWG avoided 52% of LGA (32). 
Finally, total GWG was not the only important factor 
in our study; weight gain in the third trimester also 
independently influenced LGA risk. A trend towards 
LGA risk was previously reported in women with 
excessive GWG after GDM diagnosis (34).
Insufficient GWG and its influence on LGA have 
been less commonly evaluated. A tendency toward a 
decreased LGA risk was previously reported in obese 
GDM women, as well as in overweight women (aRR 
1.05, 95% CI: 0.68, 4.19), with a risk magnitude 
similar to ours (aRR 1.17 (95% CI: 0.42, 3.29) (6). The 
protective effect of lower GWG on LGA risk compared 
to excessive gaining was expected, as we compared 
two extremes, but it is worth saying that women with 
insufficient GWG had a trend toward delivering more 
LGA babies than those gaining adequate weight. We 
believe that the independent effects of hyperglycemia 
and increased BMI could prevail over that of GWG 
because their additive effects, which are mediated 
through maternal hyperlipidemia and relative insulin 
insufficiency, further stimulate insulin secretion by the 
fetal pancreas, promoting intrauterine overgrowth (21). 
Appropriate treatment strategies, including reduced 
weight gain, potentially counteract these metabolic 
effects (35).
The main strength of our study is the possibility 
to evaluate the 2009 IOM recommendation on GWG 
in a mixed ethnic cohort with a typical GDM profile 
of excessive BMI at the beginning of pregnancy. 
In addition to the well-known effects of excessive 
GWG, we demonstrated that less than recommended 
GWG might not be deleterious in GDM pregnancies. 
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A study limitation, the influence of treatment on 
pregnancy outcomes, is inherent to the study design 
and is mitigated by the similar antenatal care offered 
throughout the time period.
In conclusion, only one quarter of this cohort 
achieved weight gain within the 2009 IOM guidance, 
perhaps indicating that specific ranges should be 
tailored for GDM pregnancies. Less than currently 
recommended GWG should be avoided in normal BMI 
women, although it may be suitable for overweight and 
obese women because it prevents excessive birth weight. 
Excessive GWG should be prevented in overweight and 
obese women to reduce the risk of large for gestational 
age babies.
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